{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(11)"],"submitter":["Fukao Y"],"pubmed_abstract":["In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1"],"journal":["Journal of clinical medicine"],"pagination":["3173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9181435"],"repository":["biostudies-literature"],"pubmed_title":["Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy."],"pmcid":["PMC9181435"],"pubmed_authors":["Jeong KH","Lee M","Lee SH","Kato R","Kano T","Fukao Y","Suzuki H","Kim JS","Nihei Y","Makita Y","Chang JM","Suzuki Y","Nakayama M"],"additional_accession":[]},"is_claimable":false,"name":"Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.","description":"In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-05-29T21:21:20.89Z","creation":"2025-02-19T03:51:57.267Z"},"accession":"S-EPMC9181435","cross_references":{"pubmed":["35683557"],"doi":["10.3390/jcm11113173"]}}